Clinical trial
A Phase Ib/II Trial of AK104 Plus Anlotinib in Patients With NSCLC
NCT04646330 is registered in ClinicalTrials.gov with Akeso as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Trial of AK104 Plus Anlotinib in Patients With NSCLC
- Lead sponsor
- Akeso
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 18, 2020
- Completion date
- July 30, 2025
- Enrollment
- 114 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
nsclc